Memorial Sloan-Kettering Oct 12, 2022 Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies Premium Oct 3, 2022 Seneca Therapeutics Cleared by FDA to Start Phase I/II Oncolytic Virus Trial Sep 30, 2022 Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Sep 21, 2022 Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Jul 20, 2022 Repertoire Immune Medicines, MSK Partner to Study Immunogenic Profile in HPV-Positive Cancers Jun 29, 2022 Sarcoma Patients Should Receive Genomic Profiling More Often, Research Suggests Premium Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium Jun 5, 2022 Rectal Cancer Patient Subset Shows Complete Response to Immunotherapy in Small Study Jun 3, 2022 Biodesix, Memorial Sloan Kettering Team on Minimal Residual Disease Test May 20, 2022 MSK Starts Offering Pediatric Cancer Patients Whole-Genome, Transcriptome Sequencing Premium May 20, 2022 Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics May 6, 2022 MSK to Launch Trial of T-Cell Receptor Therapy Targeting Common Neoantigen With Pharma Partner Premium Apr 13, 2022 MSK Researchers Testing if Chemo-Induced Hypermutated Colon Cancers Respond to BMS' Opdivo Apr 12, 2022 In Sixth Year, Project GENIE Diversifying, Integrating Local Ancestry and Enhancing Clinical Data Premium Mar 18, 2022 Researchers ID Gut Microbiome Impact on CAR T-Cell Therapy Outcomes Premium Feb 22, 2022 CAR T-Cell Therapies Show Early Promise Against Advanced Prostate Cancer Premium Feb 18, 2022 Atara Biotherapeutics CAR T-Cell Mesothelioma Trial Paused After Patient Death Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Dec 9, 2021 SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
